The determinants of antihypertensive use and expenditure in patients with hypertension in the USA

Journal of Pharmaceutical Health Services Research

Volumn 5, Issue 1, 2014, Pages 11-18

  Cai, Beilei ^a   Mcadam Marx, Carrie ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Health services research; Modelling

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SERVICE; HEALTH STATUS; HUMAN; HYPERTENSION; INCOME; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH; UNITED STATES;

EID: 84894266233     PISSN: 17598885     EISSN: 17598893     Source Type: Journal    
DOI: 10.1111/jphs.12041     Document Type: Article

References (32)

1. Joffres MR etal. Estimate of the benefits of a population-based reduction in dietary sodium additives on hypertension and its related health care costs in Canada. Can J Cardiol 2007; 23: 437-443.
2. Balu S, Thomas J, III. Incremental expenditure of treating hypertension in the United States. Am J Hypertens 2006; 19: 810-816.
3. Yoon SS(S) etal. Recent Trends in the Prevalence of High Blood Pressure and its Treatment and Control, 1999-2008. National Center for Health Statistics data brief no. 48, October 2010. Hyattsville, MD: US Department of Health and Human Services, 2010. http://www.cdc.gov/nchs/data/databriefs/db48.pdf (accessed 5 June 2012).
4. Heidenreich PA etal. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123: 933-944.
5. Phillips B. The JNC 7 hypertension guidelines. JAMA 2003; 290: 1314; author reply 1314-1315.
6. Majernick TG, Madden N. The JNC 7 hypertension guidelines. JAMA 2003; 290: 1314; author reply 1314-1315.
7. Murthy GD. The JNC 7 hypertension guidelines. JAMA 2003; 290: 1313; author reply 1314-1315.
8. Brotman DJ, Frost SD. The JNC 7 hypertension guidelines. JAMA 2003; 290: 1313-1314; author reply 1314-1315.
9. Caspi O. The JNC 7 hypertension guidelines. JAMA 2003; 290: 1313; author reply 1314-1315.
10. Sackner-Bernstein J. The JNC 7 hypertension guidelines. JAMA 2003; 290: 1312; author reply 1314-1315.
11. Nelson MR. The JNC 7 hypertension guidelines. JAMA 2003; 290: 1312; author reply 1314-1315.
12. Ong HT. The JNC 7 hypertension guidelines. JAMA 2003; 290: 1312; author reply 1314-1315.
13. Egan BM etal. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303: 2043-2050.
14. Shepard DS etal. Multivariate cost-effectiveness analysis: an application to optimizing ambulatory care for hypertension. Inquiry 1995; 32: 320-331.
15. Huttin C etal. Patterns and costs for hypertension treatment in the United States: clinical, lifestyle and socioeconomic predictors from the 1987 National Medical Expenditures Survey. Clin Drug Investig 2000; 20: 181-195.
16. McDonald M etal. Hypertension healthcare expenses and use among United States community dwelling adults: findings from the medical expenditure panel surveys 1997-1998 and 2000-2001. Am J Hypertens 2005; 18(5, Suppl. S, Part 2): 112A.
17. Machlin S etal. Medical Expenditure Panel Survey: Computing Standard Errors for MEPS Estimates. January 2005. Rockville, MD: Agency for Healthcare Research and Quality, 2005. http://meps.ahrq.gov/mepsweb/survey_comp/standard_errors.jsp (accessed 6 May 2012).
18. Tian L, Huang J. A two-part model for censored medical cost data. Stat Med 2007; 26: 4273-4292.
19. Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation?: Comparing methods of modeling Medicare expenditures. J Health Econ 2004; 23: 525-542.
20. Jones AM, Yen ST. A Box-Cox double-hurdle model. Manchester Sch 2000; 68: 203-221.
21. Duan N etal. A comparison of alternative models for the demand for medical care. J Bus Econ Stat 1983; 1: 115-126.
22. Wooldrige J. Re: st: st: [Buis ML] Two part model vs Tobit vs Heckman [email correspondence] 29 June, 2011. http://www.stata.com/statalist/archive/2011-06/msg01261.html (accessed 6 May 2012).
23. Gujarati DN. Basic Econometrics, 4th edn. New York: McGraw-Hill Higher Education, 2003.
24. Wee CC etal. Health care expenditures associated with overweight and obesity among US adults: importance of age and race. Am J Public Health 2005; 95: 159-165.
25. Greene WH. Econometric Analysis, 5th edn. Upper Saddle River, NJ: Prentice Hall, 2003.
26. Watt S etal. Age, adjustment, and costs: a study of chronic illnesses. Soc Sci Med 1997; 44: 1483-1490.
27. Donohue JM etal. Sources of regional variation in Medicare Part D drug spending. N Engl J Med 2012; 366: 530-538.
28. Leavitt MO. Geographic Variation in Drug Prices and Spending in the Part D Program. Centers for Medicaid and Medicare Services Office of Research, Development, and Information (ORDI), 2009.
29. Samuelson P, Nordhaus W. Microeconomics. New York/London: McGraw-Hill Higher Education, 2004.
30. Okunade AA etal. Determinants of Thailand household healthcare expenditure: the relevance of permanent resources and other correlates. Health Econ 2010; 19: 365-376.
31. The Kaiser Commission on Medicaid and the Uninsured. The Uninsured: A Primer. Menlo Park, CA: The Henry J. Kaiser Family Foundation, 2012.
32. Gibson TB etal. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care 2005; 11: 730-740.